Recent advances have led to novel therapies like immunotherapy and targeted therapy (widely used in oncology) [16], and identifying actionable targets (e.g., EGFR, PI3K/AKT/mTOR, RAS-MAPK) has revolutionized advanced NSCLC treatment [17]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.